CRN04894 Lowers Blood Cortisol Levels, Top-line Trial Data Show

CRN04894, a first-in-class, experimental oral medication for Cushing’s disease, led to a dose-dependent drop in blood and urine cortisol levels in healthy volunteers, top-line data from a Phase 1 trial showed. According to Crinetics Pharmaceuticals, the therapy’s developer, patient studies are expected to launch later this year. In…

Oral ACTH Blocker Safely Reduces Cortisol, Early Data Show

CRN04894, a first-in-class, investigational oral medication to treat Cushing’s disease, demonstrated pharmacologic proof-of-concept with a dose-dependent suppression of cortisol, according to data from a Phase 1 study. CRN04894, developed by Crinetics Pharmaceuticals, is designed to block the interaction (antagonist) between the MC2R receptor, found specifically on the…